KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics (PVLA) Common Equity (2016 - 2026)

Palvella Therapeutics has reported Common Equity over the past 10 years, most recently at -$93.8 million for Q4 2022.

  • Quarterly Common Equity fell 284.76% to -$93.8 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was -$93.8 million through Dec 2022, down 284.76% year-over-year, with the annual reading at -$93.8 million for FY2022, 284.76% down from the prior year.
  • Common Equity was -$93.8 million for Q4 2022 at Palvella Therapeutics, down from $35.8 million in the prior quarter.
  • Over five years, Common Equity peaked at $55.3 million in Q2 2018 and troughed at -$93.8 million in Q4 2022.
  • The 5-year median for Common Equity is $45.5 million (2020), against an average of $35.9 million.
  • Year-over-year, Common Equity soared 1002.65% in 2018 and then crashed 284.76% in 2022.
  • A 5-year view of Common Equity shows it stood at $39.9 million in 2018, then increased by 28.59% to $51.4 million in 2019, then crashed by 39.58% to $31.0 million in 2020, then surged by 63.58% to $50.8 million in 2021, then crashed by 284.76% to -$93.8 million in 2022.
  • Per Business Quant, the three most recent readings for PVLA's Common Equity are -$93.8 million (Q4 2022), $35.8 million (Q3 2022), and $44.4 million (Q2 2022).